Perry A Karsen - Net Worth and Insider Trading

Perry A Karsen Net Worth

The estimated net worth of Perry A Karsen is at least $6 Million dollars as of 2024-03-28. Perry A Karsen is the see remarks of Celgene Corp and owns about 54,869 shares of Celgene Corp (CELG) stock worth over $6 Million. Perry A Karsen is the Director of Intellia Therapeutics Inc and owns about 5,000 shares of Intellia Therapeutics Inc (NTLA) stock worth over $137,550. Perry A Karsen is also the Director of Jounce Therapeutics Inc and owns about 5,000 shares of Jounce Therapeutics Inc (JNCE) stock worth over $9,400. Besides these, Perry A Karsen also holds OncoMed Pharmaceuticals Inc (OMED) . Details can be seen in Perry A Karsen's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Perry A Karsen has not made any transactions after 2020-12-17 and currently still holds the listed stock(s).

Transaction Summary of Perry A Karsen

To

Perry A Karsen Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Perry A Karsen owns 9 companies in total, including Jounce Therapeutics Inc () , Intellia Therapeutics Inc () , and Voyager Therapeutics Inc () among others .

Click here to see the complete history of Perry A Karsen’s form 4 insider trades.

Insider Ownership Summary of Perry A Karsen

Ticker Comapny Transaction Date Type of Owner
Jounce Therapeutics Inc 2017-02-01 director
Intellia Therapeutics Inc 2020-12-17 director
Voyager Therapeutics Inc 2015-11-10 director
OncoMed Pharmaceuticals Inc 2019-04-23 director
Navidea Biopharmaceuticals Inc 2014-11-10 director
Agios Pharmaceuticals Inc 2013-07-23 director
Adynxx Inc 2013-11-27 director
Graphite Bio Inc 2021-06-24 director
Jiya Acquisition Corp 2020-11-18 director

Perry A Karsen Latest Holdings Summary

Perry A Karsen currently owns a total of 4 stocks. Among these stocks, Perry A Karsen owns 54,869 shares of Celgene Corp (CELG) as of November 12, 2014, with a value of $6 Million and a weighting of 97.44%. Perry A Karsen owns 5,000 shares of Intellia Therapeutics Inc (NTLA) as of December 17, 2020, with a value of $137,550 and a weighting of 2.26%. Perry A Karsen also owns 5,000 shares of Jounce Therapeutics Inc (JNCE) as of February 1, 2017, with a value of $9,400 and a weighting of 0.15%. The other 1 stocks OncoMed Pharmaceuticals Inc (OMED) have a combined weighting of 0.15% among all his current holdings.

Latest Holdings of Perry A Karsen

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CELG Celgene Corp 2014-11-12 54,869 108.24 5,939,021
NTLA Intellia Therapeutics Inc 2020-12-17 5,000 27.51 137,550
JNCE Jounce Therapeutics Inc 2017-02-01 5,000 1.88 9,400
OMED OncoMed Pharmaceuticals Inc 2017-06-05 10,000 0.89 8,900

Holding Weightings of Perry A Karsen


Perry A Karsen Form 4 Trading Tracker

According to the SEC Form 4 filings, Perry A Karsen has made a total of 0 transactions in Celgene Corp (CELG) over the past 5 years. The most-recent trade in Celgene Corp is the sale of 39,420 shares on November 12, 2014, which brought Perry A Karsen around $4 Million.

According to the SEC Form 4 filings, Perry A Karsen has made a total of 1 transactions in Intellia Therapeutics Inc (NTLA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Intellia Therapeutics Inc is the sale of 88,764 shares on December 17, 2020, which brought Perry A Karsen around $5 Million.

According to the SEC Form 4 filings, Perry A Karsen has made a total of 0 transactions in Jounce Therapeutics Inc (JNCE) over the past 5 years. The most-recent trade in Jounce Therapeutics Inc is the acquisition of 5,000 shares on February 1, 2017, which cost Perry A Karsen around $80,000.

More details on Perry A Karsen's insider transactions can be found in the Insider Trading History of Perry A Karsen table.

Insider Trading History of Perry A Karsen

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Perry A Karsen Trading Performance

GuruFocus tracks the stock performance after each of Perry A Karsen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Perry A Karsen is 50.42%. GuruFocus also compares Perry A Karsen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Perry A Karsen within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Perry A Karsen's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Perry A Karsen

Average Relative Return

13.04%

Average relative return per transaction

Outperforming Transactions

50%

1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) 13.63 50.42 4.72 13.04 -49.26 -28.36
Relative Return to S&P 500(%) 11.15 47.59 -3.57 -5.28 -58.22 -40.64

Perry A Karsen Ownership Network

Ownership Network List of Perry A Karsen

No Data

Ownership Network Relation of Perry A Karsen


Perry A Karsen Owned Company Details

What does Jounce Therapeutics Inc do?

Who are the key executives at Jounce Therapeutics Inc?

Perry A Karsen is the director of Jounce Therapeutics Inc. Other key executives at Jounce Therapeutics Inc include 10 percent owner Concentra Merger Sub, Inc. , 10 percent owner Concentra Biosciences, Llc , and director & CEO and President Richard /ca/ Murray .

Jounce Therapeutics Inc () Insider Trades Summary

Over the past 18 months, Perry A Karsen made no insider transaction in Jounce Therapeutics Inc (). Other recent insider transactions involving Jounce Therapeutics Inc () include a net sale of 84,298 shares made by Richard /ca/ Murray , a net purchase of 85,987 shares made by Kevin C Tang , and a net sale of 16,634 shares made by Hugh M Cole .

In summary, during the past 3 months, insiders sold 0 shares of Jounce Therapeutics Inc () in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 124,313 shares of Jounce Therapeutics Inc () were sold and 85,987 shares were bought by its insiders, resulting in a net sale of 38,326 shares.

Jounce Therapeutics Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Jounce Therapeutics Inc Insider Transactions

No Available Data

Perry A Karsen Mailing Address

Above is the net worth, insider trading, and ownership report for Perry A Karsen. You might contact Perry A Karsen via mailing address: C/o Celgene Corporation, 86 Morris Avenue, Summit Nj 07901.

Discussions on Perry A Karsen

No discussions yet.